Evidence map›Paper›PMID 26668137›Full record

ReviewTherapeutic advances in respiratory disease2016

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.

Timothy E Albertson, John R Richards, Amir A Zeki

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in respiratory disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Timothy E AlbertsonDivision of Pulmonary, Critical Care Medicine, Department of Internal Medicine and VA Northern California Healthcare Center, Mather UC Davis School of Medicine, 4150 V Street, Suite 3100, Sacramento, CA 95817, USA tealbertson@ucdavis.edu.
John R RichardsDepartment Emergency Medicine, University of California, Davis, Sacramento, CA, USA.
Amir A ZekiDivision of Pulmonary, Critical Care and Sleep Medicine University of California, Davis, Sacramento, CA, USA.
University of California, Davis · USVA Northern California Health Care System · US

Funding

The Modulation of Eotaxin Expression by Statins: Implications for Asthma TherapyK08HL114882 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZEKI, AMIR A. · 2014 to 2016
$435k
NHLBI NIH HHS K08 HL114882
6 · The paper itself

Abstract

The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 μg daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 μg) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.

Indexed as

Administration, InhalationAndrostadienesAnti-Asthmatic AgentsAsthmaBenzyl AlcoholsChlorobenzenesDrug CombinationsForced Expiratory VolumeGlucocorticoidsHumansAndrostadienesAnti-Asthmatic AgentsBenzyl AlcoholsChlorobenzenesDrug Combinationsfluticasone furoateGlucocorticoidsvilanterolcombined inhalerfluticasone furoate/vilanterol trifenatateinhaled corticosteroidlong-acting β2 agonistpersistent asthmapowder inhaler

Identifiers

PMID26668137
PMCPMC5933662
OpenAlexW2264468108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.